Fort Sheridan Advisors LLC Has $7.45 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Fort Sheridan Advisors LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 51,536 shares of the company’s stock after selling 846 shares during the period. Johnson & Johnson makes up about 1.1% of Fort Sheridan Advisors LLC’s holdings, making the stock its 20th biggest position. Fort Sheridan Advisors LLC’s holdings in Johnson & Johnson were worth $7,453,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. HC Advisors LLC acquired a new position in Johnson & Johnson in the 4th quarter valued at approximately $213,000. CORDA Investment Management LLC. grew its holdings in shares of Johnson & Johnson by 2.3% during the 4th quarter. CORDA Investment Management LLC. now owns 204,217 shares of the company’s stock valued at $29,534,000 after acquiring an additional 4,575 shares in the last quarter. Linscomb Wealth Inc. increased its stake in shares of Johnson & Johnson by 1.2% in the fourth quarter. Linscomb Wealth Inc. now owns 69,832 shares of the company’s stock worth $10,099,000 after acquiring an additional 821 shares during the last quarter. Brueske Advisory Services LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth $251,000. Finally, Heritage Oak Wealth Advisors LLC acquired a new stake in Johnson & Johnson during the fourth quarter valued at $303,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Raymond James cut their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Wells Fargo & Company cut their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Finally, Morgan Stanley reduced their price objective on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Insider Activity

In other news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $165.23 on Friday. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The business has a 50 day moving average price of $150.90 and a 200 day moving average price of $156.04. The company has a market cap of $397.81 billion, a price-to-earnings ratio of 24.85, a PEG ratio of 2.56 and a beta of 0.52. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter last year, the company posted $2.29 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.3% on a year-over-year basis. Research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.00%. Johnson & Johnson’s payout ratio is 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.